NEWS
NEWS
News
See you are these fall conferences!
NEWS ISPE Boston Area Chapter Product Show September 20 | Foxboro, MA Booth #W62 22nd Annual Contract Pharma September 21-22 | New Brunswick, NJ Technology Symposium October 2-3 | Holmdel, NJ Booth #609 2023 PDA Pharmaceutical Microbiology Conference October...
read moreSummary of Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs) Guidance for Industry
NEWS Summary of Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs) Guidance for Industry In August of 2023, the FDA Center for Drug Evaluation and Research (CDER) published a guidance document for evaluating the acceptable...
read moreDirector’s Corner: Jeff Heiser
Jeff Heiser is the Chief Scientific Officer (CSO) of Microbial and Advanced Therapeutic Platforms at Boston Analytical. After graduating from the University of New Hampshire with a degree in Microbiology Research in 2007, he entered the industry working for Pfizer...
read moreExciting Updates on our Microbiology Buildout at 12 Manor Parkway!
NEWS Exciting Updates on our Microbiology Buildout at 12 Manor Parkway - Salem, NH Boston Analytical is pleased to announce that we are in the final phase of our microbiology laboratory buildout at our 12 Manor facility. This new laboratory space more than doubles the...
read moreWhere We Have Been and Where We Are Going: A Look At 2022 and Our Growth in 2023
We had a pretty remarkable 2022! Take a look at what’s in store for 2023!
read moreEssential Experts: Chathurika Rathnayake, Ph. D.
Chathurika Rathnayake, Ph. D., is the Manager of Analytical Development at Boston Analytical, Inc. in Salem, NH. She has been with Boston Analytical since 2019, serving first as a Senior Scientist, then as Group Leader, and now in her current role. She oversees a...
read moreBoston Analytical has first FDA inspection in three years – resulting in zero observations
SALEM, New Hampshire - Boston Analytical, a leading provider of analytical and microbiological testing to the pharmaceutical, biopharmaceutical, and medical device industries is pleased to announce that their most recent FDA inspection resulted in no 483 observations....
read moreNitrosamine Drug Substance-Related Impurity Testing
Nitrosamine Drug Substance-Related Impurity Testing Ensuring that drug products do not contain nitrosamine compounds is vitally important given their toxicity. Nitrosamines can only form under certain conditions (luckily), however their high toxicity predicates the...
read moreDirector’s Corner: Mark Guevarra
Mark comes to Boston Analytical with 16+ years of experience working in the pharmaceutical industry. He currently is the Director of Analytical Development at Boston Analytical. Previously Mark was a Senior Group Leader managing all analytical method...
read moreDirector’s Corner: Karina D. Allen-Ludwig, PhD
Karina has been with Boston Analytical since 2017 and is the Director and Principal Scientist in the Biological Macromolecules Laboratory. In addition, Karina has had previous experience researching and developing methods in our Analytical Development Laboratory. She...
read more